ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Researchers have found a small molecule that successfully treats a diabetes-like condition in worms and that also hits a previously unknown diabetes target, the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The work, by Young-Tae Chang of New York University and his coworkers, not only exemplifies the value of the chemical genetics approach they used to identify the agent but also could lead to a new class of diabetes medications (Nat. Chem. Biol., DOI: 10.1038/nchembio833). The researchers used a mutant form of Caenorhabditis elegans that can't grow to its normal size as a worm model of diabetes. By soaking the worms in a solution containing small molecules from a chemical library, they found a compound (shown) that "rescues" the worms and permits them to grow normally. They also confirmed that GAPDH is the agent's molecular target. Thus, GAPDH is a potential new pathway for diabetes treatment, as well as obesity and aging research, they note.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter